We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Gene-Based Lymph-Node Assay Guides Breast Surgery

By HospiMedica staff writers
Posted on 13 Nov 2006
An intra-operative, gene-based diagnostic test that detects the spread of breast cancer to the lymph nodes has been launched in Europe.

Using real time-reverse transcriptase polymerase chain reaction (RT-PCR) technology, the test detects genes that indicate metastasis of breast cells in the lymph node. More...
This genetic technology provides a rapid, standardized, objective result, reducing errors and improving reproducibility. The test can easily be performed by trained laboratory technicians, offering advantages to hospitals where pathologists are very busy or are not available.

The in vitro diagnostic test detects clinically relevant (0.2 mm) metastases in sentinel lymph node tissue removed from the breast cancer patient. Test results are reported within 30 to 40 minutes from the time the sentinel nodes are removed, versus a two-to-three day wait for results from current permanent section histology. Results from the test can be used to guide the decision to excise additional lymph nodes and to aid in patient staging. If there is no evidence of cancer in the sentinel node, it is highly unlikely that the cancer has spread to other nodes, and there may be no need for further surgery.

The CE-marked GeneSearch breast lymph node (BLN) test developed by Veridex (Warren, NJ, USA) offers an advanced alternative to more-conventional tissue pathology. The test can be performed intra-operatively and will help pathologists provide surgeons with accurate information to help them determine whether they need to perform a simple lumpectomy or a more complex axillary lymph node dissection.

Mark Myslinski, general manager of Veridex said, "By using molecular biology to guide surgeons in the operating room, second surgeries can be prevented. We believe that the combined benefits of this test--improved patient outcomes and lowered healthcare costs--underscore its value to the medical community.”

Veridex, a Johnson & Johnson company, develops cancer diagnostic products that enable earlier disease detection as well as more accurate staging, monitoring, and therapeutic selection. The company's two complementary product lines are CellSearch assays that identify, enumerate, and characterize circulating tumor cells directly from whole blood, and GeneSearch assays that use molecular technology to diagnose, stage, and more accurately characterize tumors.



Related Links:
Veridex

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Rapid Sepsis Test
SeptiCyte RAPID
Gold Member
Blood Gas Analyzer
i-Check200
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: Adobe Stock

New ECG Foundation Model Enables Broad Cardiac Diagnosis and Risk Prediction

Electrocardiograms are central to cardiovascular decision-making, but conventional artificial intelligence models are often trained for narrow tasks, such as detecting a single arrhythmia.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.